These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26722045)

  • 1. Proton Irradiation Sensitizes Radioresistant Non-small Cell Lung Cancer Cells by Modulating Epidermal Growth Factor Receptor-mediated DNA Repair.
    Park HJ; Oh JS; Chang JW; Hwang SG; Kim JS
    Anticancer Res; 2016 Jan; 36(1):205-12. PubMed ID: 26722045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
    Das AK; Sato M; Story MD; Peyton M; Graves R; Redpath S; Girard L; Gazdar AF; Shay JW; Minna JD; Nirodi CS
    Cancer Res; 2006 Oct; 66(19):9601-8. PubMed ID: 17018617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.
    Tanaka T; Munshi A; Brooks C; Liu J; Hobbs ML; Meyn RE
    Clin Cancer Res; 2008 Feb; 14(4):1266-73. PubMed ID: 18281562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New molecular targeted therapies integrated with radiation therapy in lung cancer.
    Provencio M; Sánchez A; Garrido P; Valcárcel F
    Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy.
    Ling C; Xie Y; Zhao D; Zhu Y; Xiang J; Yang J
    Cancer Gene Ther; 2012 Oct; 19(10):697-706. PubMed ID: 22863759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.
    Johung KL; Yao X; Li F; Yu JB; Gettinger SN; Goldberg S; Decker RH; Hess JA; Chiang VL; Contessa JN
    Clin Cancer Res; 2013 Oct; 19(19):5523-32. PubMed ID: 23897899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.
    Stone E; Allen HA; Saghaie T; Abbott A; Daniel R; Mead RS; Kohonen-Corish M; Plit M; Morgan L
    Intern Med J; 2014 Dec; 44(12a):1188-92. PubMed ID: 25228365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of epidermal growth factor receptor antisense morpholino oligomer on non-small cell lung cancer cell line.
    Washio K; Aoe M; Toyooka S; Mushiake H; Tsukuda K; Shimizu N
    Oncol Rep; 2003; 10(6):1967-71. PubMed ID: 14534727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
    Okumura S; Sasaki T; Minami Y; Ohsaki Y
    J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells.
    Kim W; Youn H; Kang C; Youn B
    Apoptosis; 2015 Sep; 20(9):1242-52. PubMed ID: 26033480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
    Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD
    Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
    Kim DW; Choy H
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.